Evidence map›Paper›PMID 19656409›Full record

Trial reportLipids in health and disease2009

Effect of the dietary supplement Meltdown on catecholamine secretion, markers of lipolysis, and metabolic rate in men and women: a randomized, placebo controlled, cross-over study.

Richard J Bloomer, Robert E Canale, Megan M Blankenship, Kelley G Hammond, Kelsey H Fisher-Wellman, Brian K Schilling

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Lipids in health and disease, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Evaluation of Anti-Obesity and Antidiabetic Activities ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  7. International society of sports nutrition position stand: energy drinks and energy shots.Journal of the International Society of Sports Nutrition · 2023
    Review
  8. Article
  9. Effects ofNutrients · 2021
    Review
  10. Article
  11. Review
  12. Effect of novel dietary supplement on metabolismJournal of traditional and complementary medicine · 2017
    Article
  13. Review
  14. Review
  15. Review
  16. International Society of Sports Nutrition position stand: energy drinks.Journal of the International Society of Sports Nutrition · 2013
    Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Richard J BloomerCardiorespiratory/Metabolic Laboratory, Department of Health and Sport Sciences, University of Memphis, Memphis, TN, USA. rbloomer@memphis.edu
Robert E Canale
Megan M Blankenship
Kelley G Hammond
Kelsey H Fisher-Wellman
Brian K Schilling
University of Memphis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe have recently reported that the dietary supplement Meltdown increases plasma norepinephrine (NE), epinephrine (EPI), glycerol, free fatty acids (FFA), and metabolic rate in men. However, in that investigation measurements ceased at 90 minutes post ingestion, with values for blood borne variables peaking at this time. It was the purpose of the present investigation to extend the time course of measurement to 6 hours, and to include women within the design to determine if sex differences to treatment exist.

methodsTen men (24 +/- 4 yrs) and 10 women (22 +/- 2 yrs) ingested Meltdown or a placebo, using a randomized, cross-over design with one week separating conditions. Blood samples were collected immediately before supplementation and at one hour intervals through 6 hours post ingestion. A standard meal was provided after the hour 3 collection. Samples were assayed for EPI, NE, glycerol, and FFA. Five minute breath samples were collected at each time for measurement of metabolic rate and substrate utilization. Area under the curve (AUC) was calculated. Heart rate and blood pressure were recorded at all times. Data were also analyzed using a 2 (sex) x 2 (condition) x 7 (time) repeated measures analysis of variance, with Tukey post hoc testing.

resultsNo sex x condition interactions were noted for AUC for any variable (p > 0.05). Hence, AUC data are collapsed across men and women. AUC was greater for Meltdown compared to placebo for EPI (367 +/- 58 pg x mL(-1) x 6 hr(-1) vs. 183 +/- 27 pg x mL(-1) x 6 hr(-1); p = 0.01), NE (2345 +/- 205 pg x mL(-1) x 6 hr(-1) vs. 1659 +/- 184 pg x mL(-1) x 6 hr(-1); p = 0.02), glycerol (79 +/- 8 microg x mL)-1) x 6 hr(-1) vs. 59 +/- 6 microg x mL(-1) x 6 hr(-1); p = 0.03), FFA (2.46 +/- 0.64 mmol x L(-1) x 6 hr(-1) vs. 1.57 +/- 0.42 mmol x L(-1) x 6 hr(-1); p = 0.05), and kilocalorie expenditure (439 +/- 26 kcal x 6 hrs(-1) vs. 380 +/- 14 kcal x 6 hrs(-1); p = 0.02). No effect was noted for substrate utilization (p = 0.39). Both systolic and diastolic blood pressure (p < 0.0001; 1-16 mmHg), as well as heart rate (p = 0.01; 1-9 bpm) were higher for Meltdown. No sex x condition x time interactions were noted for any variable (p > 0.05).

conclusionIngestion of Meltdown results in an increase in catecholamine secretion, lipolysis, and metabolic rate in young men and women, with a similar response for both sexes. Meltdown may prove to be an effective intervention strategy for fat loss, assuming individuals are normotensive and their treatment is monitored by a qualified health care professional.

Indexed as

Dietary SupplementsEnergy MetabolismLipolysisAdipose TissueAnalysis of VarianceAnti-Obesity AgentsArea Under CurveBiomarkersCaffeineCatecholaminesComplex MixturesCross-Over StudiesEnergy IntakeEpinephrineFatty Acids, NonesterifiedFemaleAnti-Obesity AgentsBiomarkersCaffeineCatecholaminesComplex MixturesEpinephrineFatty Acids, NonesterifiedGlycerolNorepinephrineSynephrineYohimbine

Identifiers

PMID19656409
PMCPMC2728713
OpenAlexW2099144295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.